Pharmaceutical drug prices and trends for NIZATIDINE

Subscribe to access the full database, or Start Trial
Drug Name	NDC	Price/Unit ($)	Unit	Date
NIZATIDINE 150 MG CAPSULE	42806-0299-60	0.87068	EACH	2026-03-18
NIZATIDINE 300 MG CAPSULE	00591-3138-30	0.79878	EACH	2026-03-18
NIZATIDINE 150 MG CAPSULE	00591-3137-60	0.87068	EACH	2026-03-18
NIZATIDINE 300 MG CAPSULE	00591-3138-30	0.77820	EACH	2026-02-18
NIZATIDINE 150 MG CAPSULE	42806-0299-60	0.86440	EACH	2026-02-18
>Drug Name	>NDC	>Price/Unit ($)	>Unit	>Date

Last updated: February 12, 2026

Nizatidine is a histamine-2 (H2) receptor antagonist developed by Eli Lilly, approved in 1988 for treating gastric ulcers and gastroesophageal reflux disease (GERD). It belongs to the same drug class as ranitidine and famotidine but was withdrawn from many markets due to safety concerns with similar drugs. Currently, nizatidine's market presence is limited, mainly in regions where generic versions are available.

Current Market Status

Market Presence: Primarily available in the US through generic manufacturers. Limited or no new brand-name sales since patent expiration.
Manufacturers: Several generic companies dominate production, including Mylan and Amneal.
Pricing: Generic prices are low, with over-the-counter (OTC) versions available in some regions.

Market Size and Demand

Historical Market Size: The global H2 antagonist market was valued at approximately USD 1.2 billion in 2018, declining due to shifts towards proton pump inhibitors (PPIs).
Current Demand: Nizatidine's demand is primarily driven by specific subpopulations with contraindications to PPIs, and niche hospital formulations.

Regulatory Landscape

Status in Major Markets:
- United States: FDA-approved; marketed as a prescription drug.
- Europe and Asia: Approved or available as generic; some markets may lack recent approvals post-2010.
- Market Withdrawals: Many markets removed or limited Nizatidine due to safety issues with similar drugs, notably recent concerns over NDMA impurities in ranitidine, although nizatidine was not implicated.

Price Projections

Factors Influencing Price Trends

Manufacturing costs: Stable, given the generic status.
Market demand: Limited, driven by niche uses.
Competitive landscape: Dominated by generics, with intense price competition.
Safety profile: No recent safety scares specific to nizatidine, stabilizing its position among H2 antagonists.
Regulatory barriers: Minimal, facilitating ongoing market access.

Short-Term Projections (Next 1-2 Years)

Pricing stability: Generic nizatidine remains low-cost, typically USD 0.10 to USD 0.30 per tablet.
Market growth: Expected to remain flat; any upward movement would require new indications or significant clinical data.

Medium to Long-Term Projections (3-5 Years)

Pricing trend: Likely to remain within current low ranges unless a significant shift in clinical guidelines occurs.
Market expansion: Unlikely absent new approvals or evidence supporting unmet needs.

Market Drivers and Challenges

Drivers	Challenges
Low-cost generic entry	Competition from PPIs with superior efficacy
Niche indications	Declining overall demand for H2 antagonists
Established manufacturing infrastructure	Safety concerns indirectly affecting market perception

Comparative Market Dynamics

Drug	Market Size (USD)	Patent Status	Approved Uses
Ranitidine	Previously USD 600M (2018)	Withdrawn in 2020 due to NDMA impurities	GERD, ulcers
Famotidine	USD 400M (2018)	Patented until 2024 in US	GERD, ulcers, Zollinger-Ellison syndrome
Nizatidine (generic)	Limited, mainly niche	Off-patent	GERD, ulcers in select regions

Key Takeaways

Market size: Nizatidine's market is declining; primarily a niche product with limited growth potential.
Pricing: Remains low at USD 0.10–USD 0.30 per tablet for generics.
Market drivers: Low manufacturing costs and niche demands sustain minimal pricing fluctuation.
Market risks: Competition from PPIs and stringent safety concerns limit expansion.
Future outlook: No significant price increases expected without new indications; market stability or slight decline likely.

FAQs

Why is nizatidine less prevalent than other H2 antagonists?

Market shifts favor PPIs due to superior efficacy and safety profiles, reducing demand for nizatidine.
Could safety concerns impact nizatidine’s market?

While not implicated in NDMA contamination issues like ranitidine, broader safety perceptions influence general H2 antagonist markets.
Are there opportunities for new formulations or indications?

Currently, limited. Market entry would require demonstrating significant advantages or unmet medical needs.
How does patent status affect pricing?

As an off-patent drug, nizatidine’s price remains driven by generic competition, keeping costs low.
What regions show the most promise for niche market growth?

Limited data suggest North America and select Asian markets may retain demand for specific indications.